Intro to sedative hypnotics Flashcards
Benzodiazepines drug list
Alprazolam (Xanax) Clonazepam (Klonopin) Diazepam (Valium) Lorazepam (Ativan) Midazolam (Versed) Oxazepam Quazepam Temazepam (Restoril) Triazolam
Benzodiazepine Antagonist drug list
Flumazenil
Barbiturates
drug list
Phenobarbital
Miscellaneous Sedative-Hypnotic Drugs
drug list
Buspirone (BuSpar) Eszopiclone (Lunesta) Ramelteon (Rozerem) Zaleplon (Sonata) Zolpidem (Ambien, Ambien-CR)
Sedative
Reduces anxiety, exerts calming effect
May be side effect of drugs which are not general CNS depressants (e.g., antidepressants, antihistamines, neuroleptics/antipsychotics
Hypnotic
Produces drowsiness, facilitates onset & maintenance of sleep
More pronounced CNS depression
Dose-Response Curves for Hypothetical Sedative-Hypnotics
Linear: barbiturates, alcohols, and older sedative-hypnotics
Plateau: benzodiazepines and newer sedative-hypnotics
what do Benzodiazepines
do?
Capable of: sedation, hypnosis, muscle relaxation, anxiolytic, and anticonvulsant effects
what do barbiturates do?
Capable of: mild sedation anesthesia, anxiolytic, hypnotic, and anticonvulsant effects
what do the new hypnotics do?
Useful for: sleep aid, delirium, anxiety, seizures
Mechanisms of Action
Benzodiazepines
Promote binding of GABA to GABAA receptor
Enhance GABA-induced ion currents
Increase frequency of channel opening
Barbiturates
Potentiate GABA-induced Cl- currents
Increase duration of channel opening
May activate channel directly at high concentrations
Miscellaneous
Eszopiclone, zaleplon, zolpidem: GABAA receptor agonists
Ramelteon: activates MT1 and MT2 receptors
Pharmacokinetics- Absorption & Distribution
Lipid solubility important determinant of rate of CNS entry
Most rapidly absorbed into blood following oral administration
Sedative-hypnotics cross CNS, placental barrier, and breast milk
Pharmacokinetics- Biotransformation of benzodiazepines
Hepatic drug-metabolizing enzyme systems important mediators of drug inactivation and elimination
Benzodiazepines
- Hepatic metabolism for clearance of all benzodiazepines
- Most undergo phase I reactions (CYP3A4) followed by glucuronidation (phase II)
- Cumulative toxicity
3 drugs that only require conjugation, useful for those with hepatic impairment
Lorazepam
Oxazepam
Torazepam
Pharmacokinetics: Biotransformation of barbiturates
Hepatic drug-metabolizing enzyme systems important mediators of drug inactivation and elimination
Barbiturates
Most undergo hepatic metabolism and excreted in urine as glucuronide conjugates (phenobarbital 20-30% excreted unchanged)
Long t1/2’s and cumulative toxicity
Pharmacokinetics: Biotransformation of newer hypnotics
CYP3A4 plays a role in eszopiclone, zolpidem, and zaleplon metabolism
Relatively short t1/2’s
Fast metabolism (quick onset) with long half-lives
oxidation- ex. alprazolam, diazepam
Intermediate metabolism (intermediate onset after oral administration)
Estazolam
Oxazepam
Lorazepam
Temazepam
fast onset with shorter halflives
eszopiclone
zaleplon
Zolopidem
Tolerance
Decrease in responsiveness to a drug following repeated exposure (common feature of sedative-hypnotic use)
Cross-tolerance – repeated use of a drug produces tolerance to that drug but also drugs in same structural/mechanistic class
Mechanisms:
- Down-regulation of GABAA receptors (benzodiazepines)
- Enzyme induction (barbiturates)
(remembering phenobarbital induces its own metabolism)
Dependence
Sedative-Hypnotics: relief of anxiety, euphoria, disinhibition, and promotion of sleep
Physiologic – increased anxiety, insomnia, CNS excitability
Psychologic – cravings, irritability, insomnia, depression
When use becomes compulsive, physiologic dependence and tolerance likely to develop
Adverse Effects
Dose-related CNS depression
Low doses – drowsiness, impaired judgment, & diminished motor skills
Severe toxicity – respiratory depression
Increased sensitivity to sedative-hypnotics in the elderly and in patients with cardiovascular disease, respiratory disease, or hepatic impairment
Flumazenil
MOA: competitive antagonist at benzodiazepine site on GABAA receptor
Blocks actions of – benzodiazepines, zolpidem, zaleplon, and eszopiclone
Does not block – barbiturates, buspirone, ramelteon
**PK: short t1/2 0.7-1.3 hours (repeated doses necessary)
Use: reverse CNS depressant effects of benzodiazepine overdose and shorten recovery following anesthetic and diagnostic procedures
ADRs: agitation, confusion, dizziness, nausea
Ramelteon
MOA: agonist at MT1 and MT2 melatonin receptors
PK: extensive first-pass effect
Use: treatment of insomnia (difficulty with sleep onset)
ADRs: dizziness, somnolence, fatigue
- no abuse potential